Clinical mass spectrometry：principles of mass spectrometry for clinical laboratories

doi:10.3969/j.issn.1673-8640.2018.01.0001

Abstract

Abstract:

Mass spectrometry （MS） is a fast growing area in clinical laboratories due to its exceptional specificity,high sensitivity and ability to detect multiple compounds simultaneously. Several types of mass spectrometers are being used in clinical laboratories globally. As a result,tremendous improvements in assay performance are in process. This review is intended as a basic introduction to MS and describes the history of MS in clinical laboratories,instrumentation,ionization techniques and sample preparation. The review also discusses challenges to implementation in clinical laboratories and discussions on future instrumentation and future uses of MS.

Key words: Clinical Laboratory, Mass spectrometry, Assay principle

CLC Number:

R446.5

ZHANG Yan, Thomas Jackson. Clinical mass spectrometry：principles of mass spectrometry for clinical laboratories[J]. Laboratory Medicine, 2018, 33(1): 1-9.

Figures/Tables 3

References 50

[1]	YOST R A, ENKE C G.Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation[J]. Anal Chem, 1979,51(12):1251-1264.
[2]	SHACKLETON C.Clinical steroid mass spectrometry: a 45-year history culminating in HPLC-MS/MS becoming an essential tool for patient diagnosis[J]. J Steroid Biochem Mol Biol,2010,121(3-5): 481-490.
[3]	LEHOTAY D C, CLARKE J T.Organic acidurias and related abnormalities[J]. Crit Rev Clin Lab Sci, 1995,32(4): 377-429.
[4]	MILLINGTON D S, KODO N, NORWOOD D L, et al.Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism[J]. J Inherit Metab Dis, 1990,13(3): 321-324.
[5]	BLAKLEY C R, VESTAL M L.Thermospray interface for liquid chromatography/mass spectrometry[J]. Anal Chem, 1983,55(4): 750-754.
[6]	ADAWAY J E, KEEVIL B G, OWEN L J.Liquid chromatography tandem mass spectrometry in the clinical laboratory[J]. Ann Clin Biochem, 2015,52(Pt 1): 18-38.
[7]	COTTER R J, SWATKOSKI S, BECKER L, et al.Time-of-flights and traps: from the Histone Code to Mars[J]. Eur J Mass Spectrom(Chichester), 2010, 16(3): 331-340.
[8]	PLASS W R, DICKEL T, SCHEIDENBERGER C.Multiple-reflection time-of-flight mass spectrometry[J]. Int J Mass Spectrom,2013, 349-350 : 134-144.
[9]	COMISAROW M B, MARSHALL A G.Frequency-sweep Fourier transform ion cyclotron resonance spectroscopy[J]. Chem Phys Lett, 1974,26(4): 489-490.
[10]	COMISAROW M B, MARSHALL A G.Fourier transform ion cyclotron resonance spectroscopy[J]. Chem Phys Lett, 1974,25(2): 282-283.
[11]	MAKAROV A.Electrostatic axially harmonic orbital trapping: a high-performance technique of mass analysis[J]. Anal Chem, 2000,72(6): 1156-1162.
[12]	DE HOFFMANN E.Tandem mass spectrometry: a primer[J]. J Mass Spectrom, 1996,31(2): 129-137.
[13]	KEBARLE P, VERKERK U H.A brief overview of the mechanisms involved in electrospray mass spectrometry[M].Weinheim:Wiley-VCH Verlag GmbH and Co. KGaA, 2010:1-35.
[14]	GOHLKE R S.Time-of-flight mass spectrometry and gas-liquid partition chromatography[J]. Anal Chem, 1959,31: 535-541.
[15]	GOHLKE R S, MCLAFFERTY F W.Early gas chromatography/mass spectrometry[J]. J Am Soc Mass Spectrom, 1993,4(5): 367-371.
[16]	WILKINS C L, LAY J O.Identification of microorganisms by mass spectrometry[J]. Chem Anal, 2006,2006:169.
[17]	TAKÁTS Z, WISEMAN J M, GOLOGAN B, et al. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization[J]. Science, 2004,306(5695): 471-473.
[18]	WAGNER M, TONOLI D, VARESIO E, et al.The use of mass spectrometry to analyze dried blood spots[J]. Mass Spectrom Rev, 2016,35(3): 361-438.
[19]	RODUSHKIN I, ENGSTRÖM E, BAXTER D C. Isotopic analyses by ICP-MS in clinical samples[J]. Anal Bioanal Chem, 2013,405(9): 2785-2797.
[20]	DELAFIORI J, RING G, FUREY A.Clinical applications of HPLC-ICP-MS element speciation: a review[J]. Talanta, 2016,153: 306-331.
[21]	LUNDANES E, REUBSAET L, GREIBROKK T.Chromatography: basic principles, sample preparations and relate. Methods [M]. New Jersey:John Wiley and Sons,2013.
[22]	HSIEH Y.Supercritical fluid chromatography-mass spectrometry[J]. Boca Raton:CRC Press,2010:277-296.
[23]	PONTILLO C, FILIP S, BORRAS D M, et al.CE-MS-based proteomics in biomarker discovery and clinical application[J]. Proteomics Clin Appl, 2015,9(3-4): 322-334.
[24]	GELL D A, GRANT R P, MACKAY J P.The detection and quantitation of protein oligomerization[J]. Adv Exp Med Biol, 2012,747: 19-41.
[25]	LINGE K L, JARVIS K E.Quadrupole ICP-MS: introduction to instrumentation, measurement techniques and analytical capabilities[J]. Geostand Geoanal Res, 2009,33(4): 445-467.
[26]	MEYER G M, MAURER H H, MEYER M R.Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology[J]. Bioanalysis, 2016,8(5): 457-481.
[27]	MESMIN C, VAN OOSTRUM J, DOMON B.Complexity reduction of clinical samples for routine mass spectrometric analysis[J]. Proteomics Clin Appl, 2016,10(4): 315-322.
[28]	PERSONA K, MADEJ K, KNIHNICKI P, et al.Analytical methodologies for the determination of benzodiazepines in biological samples[J]. J Pharm Biomed Anal, 2015,113: 239-264.
[29]	BOURGOGNE E, WAGNER M.Sample preparation and bioanalysis in mass spectrometry[J]. Ann Biol Clin(Paris), 2015,73(1): 11-23.
[30]	FARHADI K, HATAMI M, MATIN A A.Microextraction techniques in therapeutic drug monitoring[J]. Biomed Chromatogr, 2012,26(8): 972-989.
[31]	DEVENTER K, POZO O J, VERSTRAETE A G, et al.Dilute-and-shoot-liquid chromatography-mass spectrometry for urine analysis in doping control and analytical toxicology[J]. TrAC Trends Anal Chem, 2014,55: 1-13.
[32]	FRITZ J S.Solid-phase extraction: principles, techniques and applications[J]. J Am Chem Society, 2000,122(49): 12411-12412.
[33]	KUELPMANN W R, HANNAK D.Methods for clinical toxicological analysis[M]. Weinheim:Wiley-VCH Verlag GmbH and Co. KGaA, 2009:25-58.
[34]	WUDY S A, HOMOKI J.Profiling steroids by gas chromatography-mass spectrometry: clinical applications[M]. Switzerland: S Karger AG, 2003:427-449.
[35]	BAKER T C, HAN J, BORCHERS C H.Recent advancements in matrix-assisted laser desorption/ionization mass spectrometry imaging[J]. Curr Opin Biotechnol, 2017,43: 62-69.
[36]	MARCINKOWSKA M, BARALKIEWICZ D.Multielemental speciation analysis by advanced hyphenated technique-HPLC/ICP-MS: a review[J]. Talanta, 2016,161: 177-204.
[37]	THOMPSON B M, SCOTT B I, BOIANI J A.Understanding the Food and Drug Administration's jurisdiction over laboratory-developed tests and divisions between food, drug, and cosmetic act-regulated and Clinical Laboratory Improvement Amendments of 1988-regulated activities[J]. Clin Lab Med, 2016,36(3): 575-585.
[38]	LEHMANN W D.A timeline of stable isotopes and mass spectrometry in the life sciences[J]. Mass Spectrom Rev, 2017,36(1): 58-85.
[39]	ANNESLEY T M.Ion suppression in mass spectrometry[J]. Clin Chem, 2003,49(7): 1041-1044.
[40]	VILJANTO M, SCARTH J, HINCKS P, et al.Application of testosterone to epitestosterone ratio to horse urine-a complementary approach to detect the administrations of testosterone and its pro-drugs in thoroughbred geldings[J]. Drug Test Anal, 2017,9(9): 1328-1336.
[41]	CARTER G D, JONES J C, SHANNON J, et al.25-Hydroxyvitamin Dassays: potential interference from other circulating vitamin dmetabolites[J]. J Steroid Biochem Mol Biol, 2016,164: 134-138.
[42]	ZHANG Y V, ROCKWOOD A.Impact of automation on mass spectrometry[J]. Clin Chim Acta, 2015,450: 298-303.
[43]	FRENCH D, TERRAZAS E.The successful implementation of a licensed data management interface between a Sunquest(®) laboratory information system and an AB SCIEXTM mass spectrometer[J]. J Pathol Inform, 2013,4: 1.
[44]	CORTELYOU-WARD K, RAMIREZ B, ROTARIUS T.The laboratory workforce shortage: a managerial perspective[J]. Health Care Manag (Frederick), 2011,30(2): 148-155.
[45]	GARG U, ZHANG Y V.Mass spectrometry in clinical laboratory: applications in biomolecular analysis[J]. Methods Mol Biol, 2016,1378: 1-9.
[46]	STOLL D R, CARR P W.Two-dimensional liquid chromatography: a state of the art tutorial[J]. Analytical Chem, 2017,89(1): 519-531.
[47]	WEI D, LI M, KING K W, et al.Online and automated sample extraction[J]. Bioanalysis, 2015,7(17): 2227-2233.
[48]	JOHNSON-DAVIS K L, JUENKE J M, THOMAS R L, et al. Everolimus method comparison between Waters MassTrakTM Immunosuppressants XE (IUO) kit and an in-house laboratory developed LC-MS/MS method in renal transplant patients[J]. Ann Clin Lab Sci, 2015,45(1): 27-31.
[49]	SAITMAN A, METUSHI I G, MASON D S, et al.Evaluation of the Waters MassTrak LC-MS/MS assay for tacrolimus and a comparison to the Abbott architect immunoassay[J]. Ther Drug Monitor, 2016,38(3): 300-304.
[50]	FERREIRA C R, YANNELL K E, JARMUSCH A K, et al.Ambient ionization mass spectrometry for point-of-care diagnostics and other clinical measurements[J]. Clin Chem, 2016,62(1): 99-110.

名称	色谱法	待测物类别	待测物分子质量	优点	缺点
EI	GC	非极性,可挥发	低-中	质量谱重复性高	与LC不兼容
CI	GC	非极性,可挥发	低-中	GC兼容样品信息	与LC不兼容
ESI	LC,SFC,CE	极性	中-高	与许多生物样品兼容	受限于电离抑制
APCI	LC,SFC,CE	极性、极性较小	较低-中	较ESI稳定	不及ESI敏感
APPI	LC, SFC, CE	含芳香基团	较低-中	高信噪比	只能用于含芳香基团物质的检测

名称	色谱法	待测物类别	待测物分子质量	优点	缺点
EI	GC	非极性,可挥发	低-中	质量谱重复性高	与LC不兼容
CI	GC	非极性,可挥发	低-中	GC兼容样品信息	与LC不兼容
ESI	LC,SFC,CE	极性	中-高	与许多生物样品兼容	受限于电离抑制
APCI	LC,SFC,CE	极性、极性较小	较低-中	较ESI稳定	不及ESI敏感
APPI	LC, SFC, CE	含芳香基团	较低-中	高信噪比	只能用于含芳香基团物质的检测

样品制备技术	优点	缺点	样品适用性
稀释后直接进样	简单、成本低廉、快速	清除不彻底、非选择性、样品需稀释	尿液
蛋白沉淀	简单、成本低廉、快速	极低选择性、无法消除基质干扰	血液、血浆、血清
液-液萃取	具有分析物类别特异性、可放大浓度	难以实现自动化	尿液、血浆、血清、唾液
固相萃取法去除蛋白质及脂质	简单、快速（如实现自动化）、易于开发、可放大浓度、清除彻底	极低选择性	血液、血浆、血清
固相萃取	简单、快速（如实现自动化）、易于开发、可放大浓度、清除彻底	方法开发复杂、耗材成本最高	所有种类样品
固相萃取	快速（如实现自动化）、回收率高、具分析物类别特异性、可放大浓度	方法开发复杂、耗材成本最高	所有种类样品

样品制备技术	优点	缺点	样品适用性
稀释后直接进样	简单、成本低廉、快速	清除不彻底、非选择性、样品需稀释	尿液
蛋白沉淀	简单、成本低廉、快速	极低选择性、无法消除基质干扰	血液、血浆、血清
液-液萃取	具有分析物类别特异性、可放大浓度	难以实现自动化	尿液、血浆、血清、唾液
固相萃取法去除蛋白质及脂质	简单、快速（如实现自动化）、易于开发、可放大浓度、清除彻底	极低选择性	血液、血浆、血清
固相萃取	简单、快速（如实现自动化）、易于开发、可放大浓度、清除彻底	方法开发复杂、耗材成本最高	所有种类样品
固相萃取	快速（如实现自动化）、回收率高、具分析物类别特异性、可放大浓度	方法开发复杂、耗材成本最高	所有种类样品